MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Ocular Therapeutix Inc

Cerrado

SectorSanidad

11.27 1.71

Resumen

Variación precio

24h

Actual

Mínimo

10.96

Máximo

11.37

Métricas clave

By Trading Economics

Ingresos

-16M

-64M

Ventas

-6.4M

11M

Margen de beneficios

-602.342

Empleados

274

EBITDA

-20M

-64M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+56.17% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

471M

1.8B

Apertura anterior

9.56

Cierre anterior

11.27

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Ocular Therapeutix Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 jul 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 jul 2025, 23:05 UTC

Charlas de Mercado

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 jul 2025, 20:07 UTC

Ganancias

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 jul 2025, 20:06 UTC

Charlas de Mercado

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 jul 2025, 19:38 UTC

Charlas de Mercado

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 jul 2025, 19:09 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 jul 2025, 19:07 UTC

Charlas de Mercado

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 jul 2025, 19:03 UTC

Charlas de Mercado

Gold Slips as Big Buyers Pull Back -- Market Talk

15 jul 2025, 18:32 UTC

Adquisiciones, fusiones, absorciones

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Adquisiciones, fusiones, absorciones

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 jul 2025, 18:13 UTC

Charlas de Mercado

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 17:25 UTC

Adquisiciones, fusiones, absorciones

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 jul 2025, 17:24 UTC

Charlas de Mercado

Dollar Gains Strength After Inflation Data -- Market Talk

15 jul 2025, 16:49 UTC

Charlas de Mercado

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 15:42 UTC

Charlas de Mercado

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparación entre iguales

Cambio de precio

Ocular Therapeutix Inc previsión

Precio Objetivo

By TipRanks

56.17% repunte

Estimación a 12 Meses

Media 17.6 USD  56.17%

Máximo 22 USD

Mínimo 14 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocular Therapeutix Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

11

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.97 / 7.62Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

154 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.